Literature DB >> 1559308

Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling.

P J Williams1, J Lane, W Murray, M A Mergener, M Kamigaki.   

Abstract

It was the purpose of this study to evaluate the effect of quinidine administration on the population estimates of the volume of distribution (Vdpop) and clearance (CLpop) of digoxin. The data collected on 94 patients included 230 measured serum digoxin concentrations, height, age, sex, weight (wt), serum creatinine, history of digoxin and quinidine administration and the presence or absence of congestive heart failure (CHF). Using the NONMEM software program, estimates were obtained for CLpop and Vdpop. Variables tested for inclusion in the CLpop model were creatinine clearance (CLCR), CHF, wt, ideal bodyweight, quinidine (QUIN) [both as a discrete variable and in a dose-dependent manner], and body surface area. Variables tested for inclusion in the Vdpop model were CLCR, wt, ideal bodyweight, body surface area and quinidine. During model building a p-value of 0.05 was chosen for variable inclusion. The final model was as follows: CLpop (L/h) = (3.1 + 0.0516 x CLCR) x QUIN Vdpop (L) = (4.03 + 0.0832 x CLCR) x wt F = 0.82 where F is bioavailability. In the above, QUIN is 0.567 if quinidine is being concurrently administered and 1.0 if it is not. The coefficient of variation (CV) of CLpop was 44% while that of Vdpop was 48%. The residual intrasubject CV was 26%. These results compare favourably with previously derived methods of estimating digoxin CLpop and Vdpop but may improve on those methods due to the inclusion of quinidine in the model. These better estimates should result in improved initial dosage of digoxin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1559308     DOI: 10.2165/00003088-199222010-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  30 in total

1.  Association between clinical cardiac status, laboratory parameters, and digoxin usage.

Authors:  D H Huffman; J W Crow; P Pentikäinen; D L Azarnoff
Journal:  Am Heart J       Date:  1976-01       Impact factor: 4.749

2.  Variation in biologic availability of digoxin from four preparations.

Authors:  J Lindenbaum; M H Mellow; M O Blackstone; V P Butler
Journal:  N Engl J Med       Date:  1971-12-09       Impact factor: 91.245

Review 3.  Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

4.  Effects of quinidine on serum digoxin concentration: a prospective study.

Authors:  D R Mungall; R P Robichaux; W Perry; J W Scott; A Robinson; T Burelle; D Hurst
Journal:  Ann Intern Med       Date:  1980-11       Impact factor: 25.391

5.  The distribution and excretion of tritiated substances in experimental animals following the administration of digoxin-3H.

Authors:  C E Harrison; R O Brandenburg; P A Ongley; A L Orvis; C A Owen
Journal:  J Lab Clin Med       Date:  1966-05

6.  Digoxin-quinidine interaction in patients with renal failure.

Authors:  R Hirschberg; K Schaefer; D von Herrath; G Kreutz; H Kewitz
Journal:  Klin Wochenschr       Date:  1981-05-15

7.  Interaction between quinidine and digoxin.

Authors:  E B Leahey; J A Reiffel; R E Drusin; R H Heissenbuttel; W P Lovejoy; J T Bigger
Journal:  JAMA       Date:  1978-08-11       Impact factor: 56.272

8.  Spironolactone-induced changes in digoxin kinetics.

Authors:  S Waldorff; J D Andersen; N Heebøll-Nielsen; O G Nielsen; E Moltke; U Sørensen; E Steiness
Journal:  Clin Pharmacol Ther       Date:  1978-08       Impact factor: 6.875

9.  Calculation of serum digoxin levels in patients with normal and impaired renal function.

Authors:  M F Paulson; P G Welling
Journal:  J Clin Pharmacol       Date:  1976 Nov-Dec       Impact factor: 3.126

10.  The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin. A prospective study.

Authors:  E B Leahey; J A Reiffel; E G Giardina; J T Bigger
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391

View more
  11 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice.

Authors:  Xiao-dan Zhou; Yan Gao; Zheng Guan; Zhong-dong Li; Jun Li
Journal:  Acta Pharmacol Sin       Date:  2010-06       Impact factor: 6.150

3.  Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.

Authors:  J R Wade; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1993-04

4.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

Authors:  J R Wade; S L Beal; N C Sambol
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

Review 5.  Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model.

Authors:  E Yukawa; F Suematu; M Yukawa; M Minemoto; S Ohdo; S Higuchi; Y Goto; T Aoyama
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Population pharmacokinetics of ondansetron: a covariate analysis.

Authors:  D P de Alwis; L Aarons; J L Palmer
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

8.  Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review.

Authors:  Mariam Abdel Jalil; Noura Abdullah; Mervat Alsous; Khawla Abu-Hammour
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-05       Impact factor: 2.441

Review 9.  A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population.

Authors:  Mariam H Abdel Jalil; Noura Abdullah; Mervat M Alsous; Mohammad Saleh; Khawla Abu-Hammour
Journal:  Br J Clin Pharmacol       Date:  2020-04-01       Impact factor: 4.335

10.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.

Authors:  Björn Hornestam; Markus Jerling; Mats O Karlsson; Peter Held
Journal:  Eur J Clin Pharmacol       Date:  2003-02-19       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.